← Back to headlines
Celldex Shares Drop Following Phase 2 Barzolvolimab Results
Celldex Therapeutics experienced a decline in after-hours trading following the announcement of its phase 2 results for the drug barzolvolimab.
21 Jul, 21:10 — 21 Jul, 21:10
Sources
Showing 1 of 1 sources
